SM
DMK

Scoggin Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Scoggin Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,253
Closed -$422K – 103
2014
Q2 		$422K Sell
1,253
-890
-42% -$349K 0.02% 89
2014
Q1 		$954K Hold
2,143
– – 0.09% 76
2013
Q4 		$959K Buy
+2,143
New +$939K 0.08% 77

Other funds holding DMK

GP
Grow Partners San Diego, California $4.81M AUM 7.86% 1-Year Est. Return
Bard Associates
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Scoggin Management's DMK Position: Q3 2014 in Review

Scoggin Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2014, closing a stake of 1,253 shares — an estimated $422K sold.

Scoggin Management first reported a position in DMK in Q4 2013 and held it in 3 quarters. The position peaked at $959K in Q4 2013. 19 funds tracked by Wall St. Rank hold DMK as of Q3 2014.

  • Scoggin Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2014 after selling out during the quarter.
  • Scoggin Management sold 1,253 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2014, an estimated $422K.
  • Scoggin Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 3 quarters.
  • Scoggin Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $959K in Q4 2013.
  • 19 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2014.

Based on Scoggin Management's 13F filing for Q3 2014, filed 14 Nov 2014.